RAMOT at Tel Aviv University Ltd.

Drug Treatments Targeting Glioma Microenvironment: CD38 inhibitor as a Potential Therapeutic Approach for Glioma Treatment

Posted by RAMOT at Tel Aviv University Ltd.Responsive · Innovative Products and Technologies · Israel

Summary of the technology

The aim of this proposal is to recapitulate the effect of CD38 deficiency on glioma by the development of drugs which will act as CD38 inhibitors. CD38 is a NAD glycohydrolase and ADP-ribosyl cyclase. The extracellular enzymatic domain of CD38 uses NAD+ to catalyze the formation of the calcium mobilizing metabolites [ADP ribose (ADPR), cyclic ADPR and nicotinic acid adenine dinucleotide phosphate] involved in cellular Ca2+ mobilization. Despite being an attractive target for drug therapy for glioma (and other disorders), effective drugs which inhibit CD38 have not yet been developed. Recently several natural anthocyanines that inhibit CD38 at low ?M concentrations were identified. However, these CD38 inhibitors are not selective towards CD38, and as such are likely to cause additional and undesired side effects. The aim of this proposal is to use these lead compounds for the development of specific and potent CD38 inhibitors that will have great potential of becoming anti-glioma drugs.
Project ID : 2-2011-175

Description of the technology

Drug Treatments Targeting Glioma Microenvironment: CD38 inhibitor as a Potential Therapeutic Approach for Glioma Treatment

Gliomas are the most frequent primary tumors of the brain, and for highly malignant gliomas, Glioblastoma multiforme (GBM), there is no successful treatment. Thus, there is an urgent need to develop new therapeutic approaches to treat glioma. It has been demonstrated that the tumor microenvironment plays an essential role in glioma progression, hence, glioma tumors' microenvironment is a promising new conceptual target for the development of novel therapeutic approaches.

The majority of glioma microenvironments consistof infiltrating microglia.Wepreviously reported that CD38 regulates the microglia "activation" state in vitro and that CD38 deficiency in mice impairs the microglia-associated recovery of mice from head trauma, suggesting that CD38 deficiency abrogates microglia activation both in vitro and in vivo.

In view of these results and the important role of the tumor microenvironment in glioma expansion we reasoned that inhibition of CD38 will reduce glioma expansio. We have demonstrated that CD38 deficiency in the tumor microenvironment reduces glioma progression and prolongs the life span of glioma-bearing mice.

Project manager

Adi Elkeles
BD Manager

Project researchers

Reuven Stein
T.A.U Tel Aviv University, Life Sciences
Neurobiology

Micha Fridman
T.A.U Tel Aviv University, Exact Sciences
School of Chemistry

Related keywords

  • Medicine, Human Health
  • Medical Technology / Biomedical Engineering
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Microbiology Technology
  • Bioinformatics Technology
  • Micro- and Nanotechnology related to Biological sciences
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Bioinformatics Market
  • Therapeutic
  • Clinical Medicine
  • Life Sciences and Biotechnology
  • Pharmaceutical Indications
  • Oncology / Cancer
  • Life Sciences and Biotechnology
  • small molecules
  • oncology

About RAMOT at Tel Aviv University Ltd.

Technology Transfer Office from Israel

Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.